GORESP DIGIHALER

This brand name is authorized in Estonia, Lithuania, UK.

Active ingredients

The drug GORESP DIGIHALER contains a combination of these active pharmaceutical ingredients (APIs):

1	Budesonide UNII Q3OKS62Q6X - BUDESONIDE
	Budesonide is a glucocorticosteroid with a high local anti-inflammatory effect. At doses clinically equivalent to systemically acting glucocorticosteroids, budesonide gives significantly less HPA axis suppression and has a lower impact on inflammatory markers.
	Read more about Budesonide
2	Eformoterol UNII W34SHF8J2K - FORMOTEROL FUMARATE
	Formoterol is a predominantly selective β2-stimulator. Formoterol has bronchodilator activity in patients with reversible obstructive airway diseases. In humans formoterol is effective in the prophylaxis of bronchospasm induced by methacholine challenge.
	Read more about Eformoterol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GORESP DIGIHALER Inhalation powder	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03AK07	Formoterol and budesonide	R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AK Adrenergics and other drugs for obstructive airway diseases
Discover more medicines within R03AK07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1815971, 1815982, 1815993, 1816006, 1816017, 1816028
LT	Valstybinė vaistų kontrolės tarnyba	1089846, 1089847, 1089848, 1089849, 1089850, 1089851